The demo realized the two its primary endpoints, with semaglutide 2.four mg demonstrating statistically considerable and exceptional improvements in liver fibrosis with no worsening of steatohepatitis, together with resolution of steatohepatitis without any worsening of liver fibrosis in people with MASH in comparison to placebo.oneIn case you have